Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia [PDF]
BMC Cancer, 2023 Background Thrombocytopenia is a common complication in cancer patients undergoing chemotherapy. Chemotherapy-induced thrombocytopenia (CIT) leads to dose reduction and treatment delays, lowering chemotherapy efficacy and survival rate.
Jiwon Shin +7 more
doaj +6 more sources
Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment [PDF]
Current OncologyChemotherapy-induced thrombocytopenia (CIT) is a common yet underrecognized complication of systemic chemotherapy, particularly in gastrointestinal (GI) cancers. Despite progress in targeted and immune-based therapies, platinum-based and fluoropyrimidine
Supriya Peshin +5 more
doaj +6 more sources
Chemotherapy-induced thrombocytopenia: literature review [PDF]
Discover Oncology, 2023 Chemotherapy-induced thrombocytopenia (CIT) is a common condition that frequently results in reduced chemotherapy dosages, postponed treatment, bleeding, and unfavorable oncological outcomes.
Ai Gao, Linlin Zhang, Diansheng Zhong
doaj +4 more sources
Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature [PDF]
Cancer MedicineChemotherapy‐induced thrombocytopenia (CIT) is a common challenge of cancer therapy and can lead to chemotherapy dose reduction, delay, and/or discontinuation, affecting relative dose intensity, and possibly adversely impacting cancer care.
Gerald A. Soff +4 more
doaj +4 more sources
Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia? [PDF]
Research and Practice in Thrombosis and HaemostasisChemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy for solid tumors that results in increased bleeding risk and chemotherapy dose reductions, treatment delays, and agent discontinuation.
Hanny Al-Samkari
doaj +3 more sources
Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors [PDF]
Research and Practice in Thrombosis and HaemostasisBased on real-world research, we aimed to systematically evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors.
Yuan Liu +6 more
doaj +4 more sources
Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use [PDF]
Research and Practice in Thrombosis and Haemostasis, 2022 Background Chemotherapy‐induced thrombocytopenia (CIT) is common during treatment with antineoplastic therapies and may adversely impact chemotherapy dose intensity. There is no approved therapy for CIT.
Cy R. Wilkins +7 more
doaj +4 more sources
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies [PDF]
Haematologica, 2022 Chemotherapy-induced thrombocytopenia (CIT) is a common complication of the treatment of non-hematologic malignancies. Many patient-related variables (e.g., age, tumor type, number of prior chemotherapy cycles, amount of bone marrow tumor involvement ...
David J. Kuter
doaj +4 more sources
Incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia in nasopharyngeal carcinoma [PDF]
Cancer Medicine, 2023 Objectives This study aimed to investigate the incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC).
Lu‐Lu Zhang +11 more
doaj +4 more sources
The predictive model for risk of chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China [PDF]
Scientific Reports, 2023 Chemotherapy-related thrombocytopenia (CIT) is a significant adverse event during chemotherapy, which can lead to reduced relative dose intensity, increased risk of serious bleeding and additional medical expenditure.
Shishi Zhou +9 more
doaj +2 more sources